Remicade lawsuit: Pfizer accuses Johnson & Johnson of 'anticompetitive practices'

archive.today
webpage capture

Saved from

no other snapshots from this url |

26 Aug 2021 04:40:08 UTC

All snapshots | from host www.usatoday.com
Webpage Screenshot
share download .zip report bug or abuse donate

Critical on-the-ground reporting as low as $4.99 per month Subscribe now
MONEY

# Pfizer accuses Johnson & Johnson of 'anticompetitive practices' in lawsuit

Nathan Bomey
USA TODAY
Published 10:05 a.m. ET Sep. 20, 2017 Updated 3:44 p.m. ET Sep. 20, 2017
Pfizer filed a lawsuit against fellow pharmaceutical giant Johnson & Johnson over "anticompetitive practices" in a go-for-the-throat showdown involving the drug industry's treatment of medicines that are similar to the originals.
Johnson & Johnson
In the suit, Pfizer accuses J&J of "exclusionary contracts" and price manipulation "to maintain its monopoly" for a drug used to treat rheumatoid arthritis, Crohn's disease and other afflictions.
If J&J is found liable, the price of its treatment could theoretically come down amid stiffer competition from Pfizer. That would potentially spell relief for patients, although drug pricing is highly complex and dependent on many factors.
Technology might be about to change the healthcare industry forever
A number of tech companies have been looking at ways to bring data analytics and artificial intelligence into the healthcare sector. Newslook
The brawl between Pfizer and J&J centers on the competition between J&J's Remicade and Pfizer's biosimilar alternative, Inflectra, which launched in late 2016.
Pfizer alleges J&J threatened to withhold rebates from insurers that had determined Inflectra was an acceptable medical alternative to Remicade. The threats, Pfizer said, caused insurers to reverse course.
J&J also offered discounts on Remicade to health care providers in exchange for their pledge not to carry Inflectra, Pfizer alleges.
"These anticompetitive practices are preventing physicians from trying and patients from accessing the biosimilar," Pfizer said in a statement.
J&J rejected Pfizer's allegations.
"We are effectively competing on value and price and, to date, Pfizer has failed to demonstrate sufficient value to patients, providers, payers and employers,” said Scott White, president of J&J's Janssen Biotech unit, in a statement. "Competition is bringing down the overall cost of Remicade and will continue to bring down costs in the future. There is no merit to this lawsuit.”
The accusations are pegged to antitrust laws and 2010's Biologics Price Competition and Innovation Act, which was aimed at providing an abbreviated route to the market for biosimilar treatments.
After the lawsuit was disclosed Wednesday, Pfizer's stock rose 1.3% to $35.90 in afternoon trading. J&J shares fell 1.6% to $133.10.
Trump to drug executives: Lower prices
President Donald Trump says he wants to lower drug prices and bring pharmaceutical companies back to the United States. (Jan. 31) AP
Follow USA TODAY reporter Nathan Bomey on Twitter @NathanBomey.
We're always working to improve your experience. Let us know what you think.

0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%